AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 52 min read$UTHR

EDGEMOND JAMES sold $591K of UTHR

EDGEMOND JAMES (CFO AND TREASURER) sold 1,086 shares of UNITED THERAPEUTICS Corp (UTHR) at $544.11 ($0.59M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EDGEMOND JAMES
Published Jun 5, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/positioning but does not, by itself, indicate new operational or clinical developments.

02

Market read

Traders may treat it as a mild sentiment signal, but the 10b5-1 structure typically limits fundamental interpretation.

03

What to watch

Check whether the executive has a pattern of sales across multiple filings and whether any other insiders are buying/selling around the same window.

Relevance 7/10Novelty 6/10Timing: Filed after-hours (SEC EDGAR) for a sale executed 2026-06-04

Background

This is a SEC Form 4 insider transaction disclosure for United Therapeutics, indicating an officer sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics CFO and treasurer Edgemond James sold $590.9K of UTHR shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for follow-on selling or any change in insider behavior.

Evidence & confidence

The filing is a routine Form 4 disclosure with explicit 10b5-1 pre-arrangement, reducing the likelihood of immediate fundamental information.

Market effects

Sector

Minimal; this is company-specific insider activity without new drug, trial, or regulatory information.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

10b5-1 sales can be purely liquidity-driven; the market may overreact if it treats the sale as discretionary.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the insider transaction disclosure (Form 4).

  • insider
    Edgemond James

    CFO and treasurer who sold 1,086 shares on 2026-06-04 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$UTHRMed

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.

quiverquant.com4 min
AUG 5
$UTHRMed

UNITED THERAPEUTICS Corp (UTHR): Results of Operations and Financial Condition

UNITED THERAPEUTICS Corp (UTHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 uthrq22026-ex991.htm EX-99.1 Document Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2026 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 5, 2026: United Therapeutics Corporation (Nasdaq: UTHR ), a

SEC EDGAR 8-K7 min